started · updated
Dupilumab linked to improved growth in children with severe atopic dermatitis
A phase 3 clinical trial and open-label extension study have found that dupilumab treatment is associated with improved height growth and bone mineralization markers in children aged 6 to 11 with severe atopic dermatitis (AD).
At the start of the study, children with severe AD were disproportionately represented in lower height percentiles. Among those below the 40th percentile at baseline, 31.3% of children receiving dupilumab achieved a height increase of at least 5 percentile points by week 16, compared to 15.5% in the placebo group. By week 52, this figure rose to 50.7% for the dupilumab group.
Researchers also observed significant improvements in bone alkaline phosphatase (BALP) levels, a biomarker for bone mineralization, in patients treated with dupilumab. Medical experts note that moderate to severe atopic dermatitis may negatively affect bone growth and mineral density in pediatric patients, making the evaluation of growth-related outcomes essential during treatment.